
    
      Subjects will receive neoadjuvant cisplatin-based chemotherapy followed by radical cystectomy
      per standard of care. CTC and Aurora kinase expression patterns will be analyzed in subject
      specimens for correlation with clinicopathologic outcome. Subjects will be on study for a
      total of five years following cystectomy.
    
  